Thus, the choice of this particular recombinant VV was justified by its enhanced specificity for tumor cells, resulting from the lack of TK, and by previously demonstrated efficiency in targeting highly immunosuppressive tumors (such as triple-negative breast cancer), allowing us to suggest its efficiency as a therapy for GBM. The gene discussed is TKT; the disease is neoplasm.